IMPORTANCE of PRETREATMENT 18F-FDG PET/CT TEXTURE ANALYSIS in PREDICTING EGFR and ALK MUTATION in PATIENTS with NON-SMALL CELL LUNG CANCER

被引:10
作者
Aguloglu, Nursin [1 ]
Aksu, Aysegul [1 ]
Akyol, Murat [1 ]
Katgi, Nuran [1 ]
Doksoz, Tugce Ciftci [1 ]
机构
[1] Bahcesehir Cam & Sakura Hastanesi, Istanbul, Turkey
来源
NUKLEARMEDIZIN-NUCLEAR MEDICINE | 2022年 / 61卷 / 06期
关键词
18F-FDG-PET; CT; Lung cancer; Textural analysis; EGFR; ALK; IMAGING PHENOTYPES; SOMATIC MUTATIONS; ADENOCARCINOMA;
D O I
10.1055/a-1868-4918
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective Identification of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) mutation types is of great importance before treatment with tyrosine kinase inhibitors (TKIs). Radiomics is a new strategy for noninvasively predicting the genetic status of cancer. We aimed to evaluate the predictive power of 18F-FDG PET/CT-based radiomic features for mutational status before treatment in non-small cell lung cancer (NSCLC) and to develop a predictive model based on radiomic features. Methods Images of patients who underwent 18F-FDG PET/CT for initial staging with the diagnosis of NSCLC between January 2015 and July 2020 were evaluated using LIFEx software. The region of interest (ROI) of the primary tumor was established and volumetric and textural features were obtained. Clinical data and radiomic data were evaluated with machine learning (ML) algorithms to create a model. Results For EGFR mutation prediction, the most successful machine learning algorithm obtained with GLZLM_GLNU and clinical data was Naive Bayes (AUC: 0.751, MCC: 0.347, acc: 71.4%). For ALK rearrangement prediction, the most successful machine learning algorithm obtained with GLCM_correlation, GLZLM_LZHGE and clinical data was evaluated as Naive Bayes (AUC: 0.682, MCC: 0.221, acc: 77.4%). Conclusions In our study, we created prediction models based on radiomic analysis of 18F-FDG PET/CT images. Tissue analysis with ML algorithms are non-invasive methods for predicting ALK rearrangement and EGFR mutation status in NSCLC, which may be useful for targeted therapy selection in a clinical setting.
引用
收藏
页码:433 / 439
页数:7
相关论文
共 50 条
[21]   Quantitative 18F-FDG PET analysis in survival rate prediction of patients with non-small cell lung cancer [J].
Ma, Wenchao ;
Wang, Minshu ;
Li, Xiaofeng ;
Huang, Hui ;
Zhu, Yanjia ;
Song, Xiuyu ;
Dai, Dong ;
Xu, Wengui .
ONCOLOGY LETTERS, 2018, 16 (04) :4129-4136
[22]   Predictive Value of Initial 18F-FDG PET/CT for Identifying EGFR and KRAS Mutations in Patients with Non-small-cell Lung Cancer [J].
Topuz, Ozge Vural ;
Buyukpinarbasili, Nur .
HASEKI TIP BULTENI-MEDICAL BULLETIN OF HASEKI, 2024, 62 (05) :255-264
[23]   Comparison of 18F-FDG PET/CT and 68Ga-FAPI-04 PET/CT in patients with non-small cell lung cancer [J].
Can, Canan ;
Kepenek, Ferat ;
Komek, Halil ;
Gundogan, Cihan ;
Kaplan, Ihsan ;
Tasdemir, Bekir ;
Guzel, Yunus ;
Aguloglu, Nursin ;
Karaoglan, Huseyin .
NUCLEAR MEDICINE COMMUNICATIONS, 2022, 43 (10) :1084-1091
[24]   Predictive value of multiple metabolic and heterogeneity parameters of 18F-FDG PET/CT for EGFR mutations in non-small cell lung cancer [J].
Shi, Aiqi ;
Wang, Jianling ;
Wang, Yuzhu ;
Guo, Guorong ;
Fan, Chouchou ;
Liu, Jiangyan .
ANNALS OF NUCLEAR MEDICINE, 2022, 36 (04) :393-400
[25]   Thoracic staging with 18F-FDG PET/MR in non-small cell lung cancer – does it change therapeutic decisions in comparison to 18F-FDG PET/CT? [J].
Benedikt M. Schaarschmidt ;
Johannes Grueneisen ;
Martin Metzenmacher ;
Benedikt Gomez ;
Thomas Gauler ;
Christian Roesel ;
Philipp Heusch ;
Verena Ruhlmann ;
Lale Umutlu ;
Gerald Antoch ;
Christian Buchbender .
European Radiology, 2017, 27 :681-688
[26]   Thoracic staging with 18F-FDG PET/MR in non-small cell lung cancer - does it change therapeutic decisions in comparison to 18F-FDG PET/CT? [J].
Schaarschmidt, Benedikt M. ;
Grueneisen, Johannes ;
Metzenmacher, Martin ;
Gomez, Benedikt ;
Gauler, Thomas ;
Roesel, Christian ;
Heusch, Philipp ;
Ruhlmann, Verena ;
Umutlu, Lale ;
Antoch, Gerald ;
Buchbender, Christian .
EUROPEAN RADIOLOGY, 2017, 27 (02) :681-688
[27]   Role of 18F-FDG PET in Assessment of Response in Non-Small Cell Lung Cancer [J].
Hicks, Rodney J. .
JOURNAL OF NUCLEAR MEDICINE, 2009, 50 :31S-42S
[28]   An initial study on the comparison of diagnostic performance of 18F-FDG PET/MR and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer: Focus on pleural invasion [J].
Wang, Ma-li ;
Zhang, He ;
Yu, Hao-jun ;
Tan, Hui ;
Hu, Ling-zhi ;
Kong, Han-jing ;
Mao, Wu-jian ;
Xiao, Jie ;
Shi, Hong-cheng .
REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2023, 42 (01) :16-23
[29]   Integrated 18F-FDG PET/CT parameter defines metabolic oligometastatic non-small cell lung cancer [J].
Ma, Rong ;
Zhao, Qian ;
Zhao, Ren ;
Li, Juan ;
Wang, Yan-Yang .
NUCLEAR MEDICINE COMMUNICATIONS, 2022, 43 (09) :1026-1033
[30]   Utility of 18F-FDG PET/CT uptake values in predicting response to neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer [J].
Zhuang, Fenghui ;
Huang, Jia ;
Wu, Junqi ;
Xu, Long ;
Zhang, Lei ;
Li, Qiang ;
Li, Chongwu ;
Zhao, Yue ;
Yang, Minglei ;
Ma, Minjie ;
She, Yunlang ;
Chen, Hezhong ;
Luo, Qingquan ;
Zhao, Deping ;
Chen, Chang .
LUNG CANCER, 2023, 178 :20-27